GRCE

GRCE is a sub-$40M clinical-stage specialty pharma whose entire value rests on a drug pipeline the numbers can't tell us anything about. The MD&A confirms this is a development story — spend goes to CROs, CMOs, clinical trials and formulation of clinical drug supplies — and there is no recurring product revenue. The FY2022 '$100M revenue' line (and the flattering P/S of 0.4, -7.8% net margin, -11.1% operating margin derived from it) is a stale-data trap: revenue is dashed out for FY2023 through FY2026, so those ratios describe a business that no longer exists. What's real is five straight years of net losses (-$42.4M, -$12.9M, -$9.57M, -$7.79M) and a -$228M accumulated deficit. You are buying an option on a clinical readout, and none of the provided data lets you price that option.

The balance sheet is the one genuine bright spot: liabilities of just $2.76M against $63.9M of equity (0.04x leverage), essentially no debt, and the stock trading below book. But $49.3M of the $66.7M in assets is intangibles and goodwill, so book value is a claim on the pipeline's worth, not hard capital — if a program fails, that carrying value is at risk of impairment, not a floor. Liquid backing is really the $17.0M of cash, and that is shrinking: down 23.3% year-on-year against $8.87M of operating cash burn, i.e. roughly two years of runway. Management asserts cash is sufficient for at least 12 months, which is a narrower statement than it sounds and points to another raise. The February 2025 private placement ($13.7M net) already drove shares up 17.7%, so further dilution at these depressed levels is the base case.